Analyst consensus rating
MapLight Therapeutics Analyst Rating: Strong Buy
MPLT is rated Strong Buy by 13 analysts with a $26.69 target. As of 2026-08-29.
Direct answer
MapLight Therapeutics's consensus rating is Strong Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $26.69.
Forecast evidence checked August 29, 2026.
Get free MapLight Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $12.60
- Average price target
- $26.69
- High price target
- $45.00
- Low price target
- $13.00
- Low target gap
- +3.2%
- Target upside
- +111.8%
- High target gap
- +257.1%
- Target range width
- 254%
- Consensus rating
- Strong Buy
- Analysts
- 13
- Evidence date
- August 29, 2026
- Valid through
- September 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for MapLight Therapeutics?
MapLight Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $26.69.
How far are MapLight Therapeutics's low and high targets from the recorded price?
The low target implies +3.2%, while the high target implies +257.1%.
How many analysts are included in MapLight Therapeutics's consensus?
The verified consensus includes 13 analysts.
How is MapLight Therapeutics's target upside or downside calculated?
The average target of $26.69 is divided by the recorded price of $12.60, then one is subtracted to produce +111.8%. This does not guarantee a future return.
When was MapLight Therapeutics's analyst forecast verified?
The data was verified on 2026-08-29. The dataset is valid through 2026-09-05.